Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID Reference The new mini-textbook by Kamps & Hoffmann PDF, 110 pages

Lung Cancer

Free Subscription 07.04.2020 3 Am J Clin Oncol 2 Am J Pathol 1 Am J Respir Crit Care Med 1 Ann Oncol 3 Ann Thorac Surg 6 Anticancer Res 5 BMC Cancer 1 Cancer Cell 1 Cancer Chemother Pharmacol 1 Cancer Epidemiol Biomarkers Prev 4 Cancer Sci 1 Clin Cancer Res 6 Clin Lung Cancer 1 Clin Nucl Med 1 Eur J Cancer 3 Eur J Cardiothorac Surg 4 Int J Oncol 3 J Cancer Res Clin Oncol 1 J Clin Invest 2 J Comput Assist Tomogr 14 J Thorac Cardiovasc Surg 6 J Thorac Oncol 4 Lancet Oncol 3 Lung Cancer 1 Mol Cancer Ther 1 N Engl J Med 1 Nat Med 1 Oncogene 5 Oncol Rep 1 Oncologist 17 PLoS One 3 Proc Natl Acad Sci U S A 1 Thorax

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Am J Clin Oncol

1. NICOLI CD, Sprague BL, Anker CJ, Lester-Coll NH, et al
   On the Importance of Rural Health: Mistaking a Forest for a Few Trees.
   Am J Clin Oncol. 2019;42:885.
   PubMed     Text format    
   
   
2. IACONO D, Osman GA, Migliorino MR, Grillo L, et al
   Intrapatient Molecular and Histologic Heterogeneity After First-generation or Second-generation TKI Therapy of NSCLC Patients: Potential Clinical Impact on Subsequent third-generation TKI Treatment.
   Am J Clin Oncol. 2019;42:845-850.
   PubMed     Text format     Abstract available
   
   
3. DALWADI SM, Savjani RR, Bernicker EH, Butler EB, et al
   A Matter of Comprehensive Informed Consent: Short-Term Mortality Rates With Definitive Treatment Options in Elderly Stage I NSCLC.
   Am J Clin Oncol. 2019;42:851-855.
   PubMed     Text format     Abstract available
   
   

   
   Am J Pathol

4. QIN H, Lu S, Thangaraju M, Cowell JK, et al
   Wasf3 deficiency reveals involvement in metastasis in a mouse model of breast cancer.
   Am J Pathol. 2019 Sep 19. pii: S0002-9440(19)30716.
   PubMed     Text format     Abstract available
   
   
5. MA T, Hu Y, Guo Y, Yan B, et al
   Tumor-Promoting Activity of Long Noncoding RNA LINC00466 in Lung Adenocarcinoma via miR-144-Regulated HOXA10 Axis.
   Am J Pathol. 2019;189:2154-2170.
   PubMed     Text format     Abstract available
   
   

   
   Am J Respir Crit Care Med

6. SEARS CR, Peikert T, Possick JD, Naidoo J, et al
   Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor-related Pneumonitis. An Official American Thoracic Society Research Statement.
   Am J Respir Crit Care Med. 2019;200:e31-e43.
   PubMed     Text format     Abstract available
   
   

   
   Ann Oncol

7. SCHULER M, Berardi R, Lim WT, de Jonge M, et al
   Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a Phase I trial.
   Ann Oncol. 2020 Mar 30. pii: S0923-7534(20)36380.
   PubMed     Text format     Abstract available
   
   

   
   Ann Thorac Surg

8. LEE DS, LaChapelle C, Taioli E, Kaufman A, et al
   Second Primary Lung Cancers Demonstrate Similar Survival With Wedge Resection and Lobectomy.
   Ann Thorac Surg. 2019;108:1724-1728.
   PubMed     Text format     Abstract available
   
   
9. INAFUKU K, Yokose T, Ito H, Narimatsu H, et al
   Should Pathologically Noninvasive Lung Adenocarcinoma Larger Than 3 cm Be Classified as T1a?
   Ann Thorac Surg. 2019;108:1678-1684.
   PubMed     Text format     Abstract available
   
   
10. WANG L, Ye G, Zhan C, Sun F, et al
    Clinical Factors Predictive of a Better Prognosis of Pulmonary Metastasectomy for Hepatocellular Carcinoma.
    Ann Thorac Surg. 2019;108:1685-1691.
    PubMed     Text format     Abstract available
    
    

    
    Anticancer Res

11. LIU Y, Huber RM, Kiefl R, Tufman A, et al
    Hedgehog Pathway Activation Might Mediate Pemetrexed Resistance in NSCLC Cells.
    Anticancer Res. 2020;40:1451-1458.
    PubMed     Text format     Abstract available
    
    
12. YAN L, Rust BM, Picklo MJ
    Plasma Metabolomic Changes in Mice With Time-restricted Feeding-attenuated Spontaneous Metastasis of Lewis Lung Carcinoma.
    Anticancer Res. 2020;40:1833-1841.
    PubMed     Text format     Abstract available
    
    
13. KIM DH, Sp N, Kang DY, Jo ES, et al
    Effect of Methylsulfonylmethane on Proliferation and Apoptosis of A549 Lung Cancer Cells Through G2/M Cell-cycle Arrest and Intrinsic Cell Death Pathway.
    Anticancer Res. 2020;40:1905-1913.
    PubMed     Text format     Abstract available
    
    
14. MOUNTZIOS G, Mavropoulou X, Koliou GA, Linardou H, et al
    Impact of Bevacizumab Versus Erlotinib on Tumor Metrics in Patients With Previously Untreated Advanced Non-small Cell Lung Cancer: A Study by the Hellenic Cooperative Oncology Group.
    Anticancer Res. 2020;40:2095-2106.
    PubMed     Text format     Abstract available
    
    
15. SVATON M, Zemanova M, Zemanova P, Kultan J, et al
    Impact of Concomitant Medication Administered at the Time of Initiation of Nivolumab Therapy on Outcome in Non-small Cell Lung Cancer.
    Anticancer Res. 2020;40:2209-2217.
    PubMed     Text format     Abstract available
    
    
16. TONE M, Inomata M, Awano N, Kuse N, et al
    Salvage Chemotherapy Following Osimertinib in Non-small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation.
    Anticancer Res. 2020;40:2239-2246.
    PubMed     Text format     Abstract available
    
    

    
    BMC Cancer

17. HARDTSTOCK F, Myers D, Li T, Cizova D, et al
    Real-world treatment and survival of patients with advanced non-small cell lung Cancer: a German retrospective data analysis.
    BMC Cancer. 2020;20:260.
    PubMed     Text format     Abstract available
    
    
18. GUAN J, Luo Z, Xiao Z, Xie Y, et al
    Treatment of consistent BRAF/HRAS gene mutation and MYC amplification radiation-induced abdominal wall angiosarcoma with low-dose apatinib: a case report.
    BMC Cancer. 2019;19:1188.
    PubMed     Text format     Abstract available
    
    
19. TENG X, Teng X
    First report of pulmonary sclerosing pneomucytoma with malignant transformation in both cuboidal surface cells and stromal round cells: a case report.
    BMC Cancer. 2019;19:1154.
    PubMed     Text format     Abstract available
    
    
20. LI Z, Shen D, Zhang J, Zhang J, et al
    Relationship between WBRT total dose, intracranial tumor control, and overall survival in NSCLC patients with brain metastases - a single-center retrospective analysis.
    BMC Cancer. 2019;19:1104.
    PubMed     Text format     Abstract available
    
    
21. XU N, Liu F, Wu S, Ye M, et al
    CHD4 mediates proliferation and migration of non-small cell lung cancer via the RhoA/ROCK pathway by regulating PHF5A.
    BMC Cancer. 2020;20:262.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Cell

22. ALAM H, Tang M, Maitituoheti M, Dhar SS, et al
    KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer.
    Cancer Cell. 2020 Mar 23. pii: S1535-6108(20)30106.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Chemother Pharmacol

23. SHOJI T, Kikuchi E, Kikuchi J, Takashima Y, et al
    Evaluating the immunoproteasome as a potential therapeutic target in cisplatin-resistant small cell and non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2020 Mar 30. pii: 10.1007/s00280-020-04061.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Epidemiol Biomarkers Prev

24. WEI Q, Deng W, Liu H, Luo S, et al
    APOB genotypes and CDH13 haplotypes in the cholesterol-related pathway genes predict non-small cell lung cancer survival.
    Cancer Epidemiol Biomarkers Prev. 2020 Apr 1. pii: 1055-9965.EPI-19-1262.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Sci

25. OKIMOTO T, Kotani H, Iida Y, Koyanagi A, et al
    Pemetrexed sensitizes human lung cancer cells to cytotoxic immune cells.
    Cancer Sci. 2020 Mar 31. doi: 10.1111/cas.14401.
    PubMed     Text format     Abstract available
    
    
26. KIMURA K, Matsumoto S, Harada T, Morii E, et al
    ARL4C is associated with initiation and progression of lung adenocarcinoma and represents a therapeutic target.
    Cancer Sci. 2020;111:951-961.
    PubMed     Text format     Abstract available
    
    
27. YANAGITANI N, Uchibori K, Koike S, Tsukahara M, et al
    Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms.
    Cancer Sci. 2020;111:932-939.
    PubMed     Text format     Abstract available
    
    
28. TAKEDA T, Yamamoto H, Suzawa K, Tomida S, et al
    YES1 activation induces acquired resistance to neratinib in HER2-amplified breast and lung cancers.
    Cancer Sci. 2020;111:849-856.
    PubMed     Text format     Abstract available
    
    

    
    Clin Cancer Res

29. VAN DEN BROECK A, Brambilla E, Moro-Sibilot D, Lantuejoul S, et al
    Editor's Note: Loss of Histone H4K20 Trimethylation Occurs in Preneoplasia and Influences Prognosis of Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2020;26:1776.
    PubMed     Text format    
    
    

    
    Clin Lung Cancer

30. MODING EJ, Liang R, Lartey FM, Maxim PG, et al
    Predictors of Respiratory Decline Following Stereotactic Ablative Radiotherapy to Multiple Lung Tumors.
    Clin Lung Cancer. 2019;20:461-468.
    PubMed     Text format     Abstract available
    
    
31. SCHULZ C, Gandara D, Berardo CG, Rosenthal R, et al
    Comparative Efficacy of Second- and Subsequent-line Treatments for Metastatic NSCLC: A Fractional Polynomials Network Meta-analysis of Cancer Immunotherapies.
    Clin Lung Cancer. 2019;20:451-460.
    PubMed     Text format     Abstract available
    
    
32. PROTO C, Signorelli D, Mallone S, Prelaj A, et al
    The Prognostic Role of TNM Staging Compared With Tumor Volume and Number of Pleural Sites in Malignant Pleural Mesothelioma.
    Clin Lung Cancer. 2019;20:e652-e660.
    PubMed     Text format     Abstract available
    
    
33. MARTIN C, Lupinacci L, Perazzo F, Bas C, et al
    Efficacy and Safety of Nivolumab in Previously Treated Patients With Non-Small-cell Lung Cancer: Real World Experience in Argentina.
    Clin Lung Cancer. 2020 Feb 26. pii: S1525-7304(20)30039.
    PubMed     Text format     Abstract available
    
    
34. GUISIER F, Piton N, Salaun M, Thiberville L, et al
    ROS1-rearranged NSCLC With Secondary Resistance Mutation: Case Report and Current Perspectives.
    Clin Lung Cancer. 2019;20:e593-e596.
    PubMed     Text format    
    
    
35. JELINEK MJ, Armstrong SA, Patel JD, Subramaniam DS, et al
    Identifying Resistance Mechanisms to Osimertinib via Blood Biopsy.
    Clin Lung Cancer. 2019;20:e597-e600.
    PubMed     Text format    
    
    

    
    Clin Nucl Med

36. KODAMA E, Kodama T, Ichikawa T, Ikoma H, et al
    18F-FDG Uptake of Localized Malignant Peritoneal Mesothelioma.
    Clin Nucl Med. 2020;45:161-163.
    PubMed     Text format     Abstract available
    
    

    
    Eur J Cancer

37. FACCHINETTI F, Mazzaschi G, Barbieri F, Passiglia F, et al
    First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status.
    Eur J Cancer. 2020;130:155-167.
    PubMed     Text format     Abstract available
    
    

    
    Eur J Cardiothorac Surg

38. ZHANG X, Jiang Y, Zhang L
    L4 lymph node dissection in left-side operable non-small-cell lung cancer: one size fits all?
    Eur J Cardiothorac Surg. 2020 Mar 25. pii: 5811875. doi: 10.1093.
    PubMed     Text format    
    
    
39. DENG HY, Wang T, Tang X
    Should the left lower paratracheal lymph node always be dissected in patients with left-sided lung cancer?
    Eur J Cardiothorac Surg. 2020 Mar 26. pii: 5811876. doi: 10.1093.
    PubMed     Text format    
    
    
40. HINO H, Saito T, Matsui H, Taniguchi Y, et al
    Utility of Geriatric Nutritional Risk Index in patients with lung cancer undergoing surgery.
    Eur J Cardiothorac Surg. 2020 Apr 1. pii: 5814344. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    

    
    Int J Oncol

41. MIRZAPOIAZOVA T, Pozhitkov A, Nam A, Mambetsariev I, et al
    Effects of selected deubiquitinating enzyme inhibitors on the proliferation and motility of lung cancer and mesothelioma cell lines.
    Int J Oncol. 2020 Apr 1. doi: 10.3892/ijo.2020.5034.
    PubMed     Text format     Abstract available
    
    
42. ZAMAGNI A, Pasini A, Pirini F, Ravaioli S, et al
    CDKN1A upregulation and cisplatinpemetrexed resistance in nonsmall cell lung cancer cells.
    Int J Oncol. 2020 Mar 24. doi: 10.3892/ijo.2020.5024.
    PubMed     Text format     Abstract available
    
    
43. DRZEWIECKA H, Jarmolowska-Jurczyszyn D, Kluk A, Galecki B, et al
    Altered expression of 17betahydroxysteroid dehydrogenase type 2 and its prognostic significance in nonsmall cell lung cancer.
    Int J Oncol. 2020 Mar 19. doi: 10.3892/ijo.2020.5014.
    PubMed     Text format     Abstract available
    
    
44. KIM JH, Ko ES, Kim D, Park SH, et al
    Cancer cellspecific anticancer effects of Coptis chinensis on gefitinibresistant lung cancer cells are mediated through the suppression of Mcl1 and Bcl2.
    Int J Oncol. 2020 Mar 24. doi: 10.3892/ijo.2020.5025.
    PubMed     Text format     Abstract available
    
    

    
    J Cancer Res Clin Oncol

45. MORMILE R
    Hyperthermia, positive feedback loop with IL-6 and risk of NSCLC progression: a tangle to unravel?
    J Cancer Res Clin Oncol. 2020;146:1101-1102.
    PubMed     Text format     Abstract available
    
    
46. GUO W, Sun S, Guo L, Song P, et al
    Elevated TOP2A and UBE2C expressions correlate with poor prognosis in patients with surgically resected lung adenocarcinoma: a study based on immunohistochemical analysis and bioinformatics.
    J Cancer Res Clin Oncol. 2020;146:821-841.
    PubMed     Text format     Abstract available
    
    
47. CHEN H, Wang A, Wang J, He Z, et al
    Target-based genomic profiling of ctDNA from Chinese non-small cell lung cancer patients: a result of real-world data.
    J Cancer Res Clin Oncol. 2020 Mar 27. pii: 10.1007/s00432-020-03192.
    PubMed     Text format     Abstract available
    
    

    
    J Clin Invest

48. SALAZAR Y, Zheng X, Brunn D, Raifer H, et al
    Microenvironmental Th9- and Th17- lymphocytes induce metastatic spreading in lung cancer.
    J Clin Invest. 2020 Mar 31. pii: 124037. doi: 10.1172/JCI124037.
    PubMed     Text format     Abstract available
    
    

    
    J Comput Assist Tomogr

49. WAN Q, Lei Q, Wang P, Hu J, et al
    Intravoxel Incoherent Motion Diffusion-Weighted Imaging of Lung Cancer: Comparison Between Turbo Spin-Echo and Echo-Planar Imaging.
    J Comput Assist Tomogr. 2020 Mar 25. doi: 10.1097/RCT.0000000000001004.
    PubMed     Text format     Abstract available
    
    
50. LI QK, Ding YK, Liu Y, Xia FF, et al
    Diagnostic Yield of Computed Tomography-Guided Percutaneous Lung Biopsy in Patients With Prior Nondiagnostic Transbronchial Biopsy.
    J Comput Assist Tomogr. 2020;44:305-309.
    PubMed     Text format     Abstract available
    
    

    
    J Thorac Cardiovasc Surg

51. SESTI J, Paul S
    Commentary: GGOogle maps for the adult lung.
    J Thorac Cardiovasc Surg. 2020;159:1580.
    PubMed     Text format    
    
    
52. NGUYEN DM, Villamizar N
    Commentary: Lower airway microbiome and non-small cell lung cancer: The beginning of a bug story.
    J Thorac Cardiovasc Surg. 2020 Feb 14. pii: S0022-5223(20)30382.
    PubMed     Text format    
    
    
53. WOLF AS
    Discussion.
    J Thorac Cardiovasc Surg. 2020;159:1556.
    PubMed     Text format    
    
    
54. PASS HI
    Commentary: "Hot" gene signatures for checkpoint response prediction: A very cool idea.
    J Thorac Cardiovasc Surg. 2020;159:1611-1612.
    PubMed     Text format    
    
    
55. PATEL S, Kim AW
    Commentary: TiME may actually tell good from bad.
    J Thorac Cardiovasc Surg. 2020;159:1613-1614.
    PubMed     Text format    
    
    
56. PASS HI
    Discussion.
    J Thorac Cardiovasc Surg. 2020;159:1609-1610.
    PubMed     Text format    
    
    
57. LOCOCO F, Torricelli F, Lang-Lazdunski L, Veronesi G, et al
    Survival results in biphasic malignant pleural mesothelioma patients: A multicentric analysis.
    J Thorac Cardiovasc Surg. 2020;159:1584-1593.
    PubMed     Text format     Abstract available
    
    
58. FELMLY LM, Gibney BC
    Commentary: Biphasic malignant mesothelioma-Survival of the fittest.
    J Thorac Cardiovasc Surg. 2020;159:1596-1597.
    PubMed     Text format    
    
    
59. WAKEAM E, Kidane B
    Commentary: Picking the winners-Leaning into selection bias.
    J Thorac Cardiovasc Surg. 2020;159:1594-1595.
    PubMed     Text format    
    
    
60. MADARIAGA ML, Lennes IT, Best T, Shepard JO, et al
    Multidisciplinary selection of pulmonary nodules for surgical resection: Diagnostic results and long-term outcomes.
    J Thorac Cardiovasc Surg. 2020;159:1558-1566.
    PubMed     Text format     Abstract available
    
    
61. NGUYEN DM, Villamizar N
    Commentary: Preoperative localization of "hard-to-find" pulmonary ground-glass opacity: There are more than one way to find the target.
    J Thorac Cardiovasc Surg. 2020;159:1581-1583.
    PubMed     Text format    
    
    
62. PARK CH, Lee SM, Lee JW, Hwang SH, et al
    Hook-wire localization versus lipiodol localization for patients with pulmonary lesions having ground-glass opacity.
    J Thorac Cardiovasc Surg. 2020;159:1571-1579.
    PubMed     Text format     Abstract available
    
    
63. SUBRAMANIAN MP
    Commentary: Much to do about nodules-Improving care with a multidisciplinary pulmonary nodule clinic.
    J Thorac Cardiovasc Surg. 2020;159:1569-1570.
    PubMed     Text format    
    
    
64. BLESSING WA, Colson YL
    Commentary: The checkpoint before checkpoint inhibitors.
    J Thorac Cardiovasc Surg. 2020;159:1614-1615.
    PubMed     Text format    
    
    

    
    J Thorac Oncol

65. GRINBERG RD, Refaely Y, Cohen LB, Shaham D, et al
    Lung Cancer in Israel.
    J Thorac Oncol. 2020;15:493-498.
    PubMed     Text format    
    
    
66. POLVERARI G, Arena V, Ceci F, Pelosi E, et al
    (18)F-FDG uptake in Asymptomatic SARS-CoV-2 (COVID-19) patient, referred to PET/CT for Non-Small Cells Lung Cancer restaging.
    J Thorac Oncol. 2020 Mar 31. pii: S1556-0864(20)30286.
    PubMed     Text format    
    
    
67. DE SOUZA GUTIERRES B, Aguiar PN Jr, Dourado BB, Alves AL, et al
    Evidence Strength of Pharmaceutical Industry Funded Clinical Trials in Metastatic Non-Small Cell Lung Cancer: A Comparison with Other Sources of Funding.
    J Thorac Oncol. 2020 Mar 23. pii: S1556-0864(20)30196.
    PubMed     Text format     Abstract available
    
    
68. YANG H
    Co-Occurring LKB1 Deficiency Determinates the Susceptibility to ERK-Targeted Therapy in RAS-Mutant Lung Cancer.
    J Thorac Oncol. 2020;15:e58-59.
    PubMed     Text format    
    
    
69. KAIRA K, Ogiwara Y, Naruse I
    Occurrence of Ventricular Fibrillation in a Patient With Lung Cancer Receiving Osimertinib.
    J Thorac Oncol. 2020;15:e54-e55.
    PubMed     Text format    
    
    
70. BONOMI L, Ghilardi L, Arnoldi E, Tondini CA, et al
    A rapid fatal evolution of Coronavirus Disease-19 (COVID-19) in an advanced lung cancer patient with a long time response to nivolumab.
    J Thorac Oncol. 2020 Mar 31. pii: S1556-0864(20)30285.
    PubMed     Text format    
    
    

    
    Lancet Oncol

71. TRIGO J, Subbiah V, Besse B, Moreno V, et al
    Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.
    Lancet Oncol. 2020 Mar 27. pii: S1470-2045(20)30068.
    PubMed     Text format     Abstract available
    
    
72. ARRIETA O, Zatarain-Barron ZL, Cardona AF
    New opportunities in a challenging disease: lurbinectedin for relapsed small-cell lung cancer.
    Lancet Oncol. 2020 Mar 27. pii: S1470-2045(20)30097.
    PubMed     Text format    
    
    
73. REALE ML, Di Maio M
    Quality of life in patients with lung cancer: the way forward.
    Lancet Oncol. 2020 Mar 23. pii: S1470-2045(20)30151.
    PubMed     Text format    
    
    
74. KOLLER M, Shamieh O, Hjermstad MJ, Hornslien K, et al
    Psychometric properties of the updated EORTC module for assessing quality of life in patients with lung cancer (QLQ-LC29): an international, observational field study.
    Lancet Oncol. 2020 Mar 23. pii: S1470-2045(20)30093.
    PubMed     Text format     Abstract available
    
    

    
    Lung Cancer

75. VERONESI G, Navone N, Novellis P, Dieci E, et al
    Favorable incremental cost-effectiveness ratio for lung cancer screening in Italy.
    Lung Cancer. 2020;143:73-79.
    PubMed     Text format     Abstract available
    
    
76. MA L, Zhang Q, Dong Y, Li H, et al
    SPECC1L-ALK: A novel gene fusion response to ALK inhibitors in non-small cell lung cancer.
    Lung Cancer. 2020 Mar 18. pii: S0169-5002(20)30347.
    PubMed     Text format    
    
    
77. BOYSEN FYNBOE EBERT E, McCulloch T, Holmskov Hansen K, Linnet H, et al
    Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patients.
    Lung Cancer. 2020;143:67-72.
    PubMed     Text format     Abstract available
    
    

    
    Mol Cancer Ther

78. FUNAZO TY, Tsuji T, Ozasa H, Furugaki K, et al
    Acquired Resistance to Alectinib in ALK-Rearranged Lung Cancer Due to ABCC11/MRP8 Overexpression in a Clinically Paired Resistance Model.
    Mol Cancer Ther. 2020 Mar 26. pii: 1535-7163.MCT-19-0649.
    PubMed     Text format     Abstract available
    
    

    
    N Engl J Med

79. BELLO F, Fagni F
    Nasal Deformity in Granulomatosis with Polyangiitis.
    N Engl J Med. 2020;382:951.
    PubMed     Text format    
    
    

    
    Nat Med

80. HATA AN, Shaw AT
    Resistance looms for KRAS(G12C) inhibitors.
    Nat Med. 2020;26:169-170.
    PubMed     Text format    
    
    

    
    Oncogene

81. WANG Y, Ma R, Liu B, Kong J, et al
    SNP rs17079281 decreases lung cancer risk through creating an YY1-binding site to suppress DCBLD1 expression.
    Oncogene. 2020 Mar 30. pii: 10.1038/s41388-020-1278.
    PubMed     Text format     Abstract available
    
    

    
    Oncol Rep

82. LV L, Zhang W, Li T, Jiang L, et al
    Hispidulin exhibits potent anticancer activity in vitro and in vivo through activating ER stress in nonsmallcell lung cancer cells.
    Oncol Rep. 2020 Mar 30. doi: 10.3892/or.2020.7568.
    PubMed     Text format     Abstract available
    
    
83. ZHANG L, Tao X, Fu Q, Ge C, et al
    Curcumin inhibits cell proliferation and migration in NSCLC through a synergistic effect on the TLR4/MyD88 and EGFR pathways.
    Oncol Rep. 2019;42:1843-1855.
    PubMed     Text format     Abstract available
    
    
84. WEI M, Li J, Qiu J, Yan Y, et al
    Costunolide induces apoptosis and inhibits migration and invasion in H1299 lung cancer cells.
    Oncol Rep. 2020 Mar 26. doi: 10.3892/or.2020.7566.
    PubMed     Text format     Abstract available
    
    
85. WANG J, Zhang ZQ, Li FQ, Chen JN, et al
    Triptolide interrupts rRNA synthesis and induces the RPL23MDM2p53 pathway to repress lung cancer cells.
    Oncol Rep. 2020 Mar 30. doi: 10.3892/or.2020.7569.
    PubMed     Text format     Abstract available
    
    
86. HU J, Shang Y, Shi X, Zhang S, et al
    Characterization of genomic alterations and the significance of PI3K/mTOR pathway mutations and tumor mutational burden in nonsmall cell lung cancer.
    Oncol Rep. 2020 Mar 23. doi: 10.3892/or.2020.7559.
    PubMed     Text format     Abstract available
    
    

    
    Oncologist

87. POPAT V, Lu R, Ahmed M, Park JY, et al
    Lack of Association Between Radiographic Tumor Burden and Efficacy of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
    Oncologist. 2020 Mar 31. doi: 10.1634/theoncologist.2019-0814.
    PubMed     Text format     Abstract available
    
    

    
    PLoS One

88. GU K, Lee HY, Lee K, Choi JY, et al
    Integrated evaluation of clinical, pathological and radiological prognostic factors in squamous cell carcinoma of the lung.
    PLoS One. 2019;14:e0223298.
    PubMed     Text format     Abstract available
    
    
89. HE Y, Liu H, Wang S, Chen Y, et al
    Prognostic nomogram predicts overall survival in pulmonary large cell neuroendocrine carcinoma.
    PLoS One. 2019;14:e0223275.
    PubMed     Text format     Abstract available
    
    
90. TAMIRAT MZ, Koivu M, Elenius K, Johnson MS, et al
    Structural characterization of EGFR exon 19 deletion mutation using molecular dynamics simulation.
    PLoS One. 2019;14:e0222814.
    PubMed     Text format     Abstract available
    
    
91. GER RB, Meier JG, Pahlka RB, Gay S, et al
    Effects of alterations in positron emission tomography imaging parameters on radiomics features.
    PLoS One. 2019;14:e0221877.
    PubMed     Text format     Abstract available
    
    
92. RAI SN, Srivastava S, Pan J, Wu X, et al
    Multi-group diagnostic classification of high-dimensional data using differential scanning calorimetry plasma thermograms.
    PLoS One. 2019;14:e0220765.
    PubMed     Text format     Abstract available
    
    
93. MARSHALL EA, Stewart GL, Sage AP, Lam WL, et al
    Beyond sequence homology: Cellular biology limits the potential of XIST to act as a miRNA sponge.
    PLoS One. 2019;14:e0221371.
    PubMed     Text format     Abstract available
    
    
94. CHEN HC, Tan EC, Liao CH, Lin ZZ, et al
    Development and validation of nomograms for predicting survival probability of patients with advanced adenocarcinoma in different EGFR mutation status.
    PLoS One. 2019;14:e0220730.
    PubMed     Text format     Abstract available
    
    
95. VINCENTEN JPL, van Essen HF, Lissenberg-Witte BI, Bulkmans NWJ, et al
    Clonality analysis of pulmonary tumors by genome-wide copy number profiling.
    PLoS One. 2019;14:e0223827.
    PubMed     Text format     Abstract available
    
    
96. CHOI W, Kim SH, Kang SH, Park JJ, et al
    Differential impact of smoking on cardiac or non-cardiac death according to age.
    PLoS One. 2019;14:e0224486.
    PubMed     Text format     Abstract available
    
    
97. MOON DH, Park CH, Kang DY, Lee HS, et al
    Significance of the lobe-specific emphysema index to predict prolonged air leak after anatomical segmentectomy.
    PLoS One. 2019;14:e0224519.
    PubMed     Text format     Abstract available
    
    
98. LU Y, Jiang J, Ren C
    The clinicopathological and prognostic value of the pretreatment neutrophil-to-lymphocyte ratio in small cell lung cancer: A meta-analysis.
    PLoS One. 2020;15:e0230979.
    PubMed     Text format     Abstract available
    
    
99. CHANG PH, Lin CR, Lee YH, Liu YL, et al
    Exercise experiences in patients with metastatic lung cancer: A qualitative approach.
    PLoS One. 2020;15:e0230188.
    PubMed     Text format     Abstract available
    
    
100. ZHANG Y, Pavlov A, Malik S, Chen H, et al
     Efficacy of a small molecule inhibitor of the transcriptional cofactor PC4 in prevention and treatment of non-small cell lung cancer.
     PLoS One. 2020;15:e0230670.
     PubMed     Text format     Abstract available
     
     
101. BERENT TE, Dorschner JM, Meyer T, Craig TA, et al
     Impaired cardiac performance, protein synthesis, and mitochondrial function in tumor-bearing mice.
     PLoS One. 2019;14:e0226440.
     PubMed     Text format     Abstract available
     
     
102. CHUN YJ, Choi JW, Hong MH, Jung D, et al
     Molecular characterization of lung adenocarcinoma from Korean patients using next generation sequencing.
     PLoS One. 2019;14:e0224379.
     PubMed     Text format     Abstract available
     
     
103. TANAKA T, Akiyoshi H, Nishida H, Mie K, et al
     Contrast-enhanced computed tomography findings of canine primary renal tumors including renal cell carcinoma, lymphoma, and hemangiosarcoma.
     PLoS One. 2019;14:e0225211.
     PubMed     Text format     Abstract available
     
     
104. KIM A, Lee SJ, Ahn J, Park WY, et al
     The prognostic significance of tumor-infiltrating lymphocytes assessment with hematoxylin and eosin sections in resected primary lung adenocarcinoma.
     PLoS One. 2019;14:e0224430.
     PubMed     Text format     Abstract available
     
     

     
     Proc Natl Acad Sci U S A

105. YIN Y, Xie CM, Li H, Tan M, et al
     The FBXW2-MSX2-SOX2 axis regulates stem cell property and drug resistance of cancer cells.
     Proc Natl Acad Sci U S A. 2019 Sep 23. pii: 1905973116.
     PubMed     Text format     Abstract available
     
     
106. LIM SB, Yeo T, Lee WD, Bhagat AAS, et al
     Addressing cellular heterogeneity in tumor and circulation for refined prognostication.
     Proc Natl Acad Sci U S A. 2019;116:17957-17962.
     PubMed     Text format     Abstract available
     
     
107. SCHMIDT L, Eskiocak B, Kohn R, Dang C, et al
     Enhanced adaptive immune responses in lung adenocarcinoma through natural killer cell stimulation.
     Proc Natl Acad Sci U S A. 2019;116:17460-17469.
     PubMed     Text format     Abstract available
     
     

     
     Thorax

108. PARK HY, Kang D, Shin SH, Yoo KH, et al
     Chronic obstructive pulmonary disease and lung cancer incidence in never smokers: a cohort study.
     Thorax. 2020 Apr 2. pii: thoraxjnl-2019-213732.
     PubMed     Text format     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: